Efficient VLP vector based on PP7 RNA stem-loop structure and application thereof to delivery of mRNA

By combining PP7 RNA stem loop structure and phage capsid protein, an efficient VLP vector was developed, which solved the problem of insufficient mRNA delivery stability and targeting in the prior art, significantly improved delivery efficiency and reduced off-target effect, and achieved More efficient CRISPR-Cas9 editing.

CN118903442APending Publication Date: 2024-11-08SHANGHAI BAILIAN BIOMEDICAL TECH CO LTD
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
CN202410971896.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing VLP vectors have stability problems, risk of immune response, low target delivery efficiency and off-target effects when delivering mRNA, making it difficult to achieve safe, efficient and efficient intracellular delivery.

Method used

Based on the combination of PP7 RNA stem loop structure and phage capsid protein, an efficient VLP vector was developed to improve mRNA delivery efficiency and CRISPR-Cas9 editing efficiency through specific binding and reduce off-target effects.

Benefits of technology

The mRNA delivery efficiency and CRISPR-Cas9 editing efficiency were significantly improved, the risk of off-target effects of traditional lentiviral delivery was reduced, and a relatively more efficient transient expression delivery vector was developed.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903442A_ABST
    Figure CN118903442A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of gene engineering, and particularly relates to an efficient VLP vector based on a PP7RNA stem-loop structure and application of the efficient VLP vector to delivery of mRNA. According to the invention, after Cas9 protein mRNA and stem-loop structure PP7RNA are fused, the PP7RNA is specifically combined with PCP in a VLP kernel, and the Cas9 protein mRNA is introduced into the VLP kernel; meanwhile, the gRNA aiming at a specific gene is cloned to a lentivirus shuttle plasmid, and finally the VLP which carries Cas9mRNA and gRNA and is similar to a lentivirus structure is assembled. The Cas9mRNA and the gRNA are delivered into the cytoplasm of the target cell by the VLP, and the'instantaneous' gene editing effect of the CRISPR-Cas9 system is exerted in the target cell by translating the cas9 protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of genetic engineering, and in particular relates to a high-efficiency VLP vector based on a PP7 RNA stem-loop structure and use thereof in delivering mRNA. Background Art

[0002] VLP (virus like particle) technology is derived from the lentiviral system, which can use the high affinity of the virus to achieve effective intracellular delivery. The delivery object can be nucleic acids, proteins, or ribonucleoproteins (RNPs), etc. However, when viruses deliver nucleic acids, most of them are delivered in the form of DNA, and the DNA delivered by lentiviruses has random genome insertions. Therefore, when delivering the CRISPR / Cas9 system, the Cas9 protein gene exists in the body for a long time and is continuously translated into Cas9 protein, which will lead to a higher probability of "off-target" effects (gene shearing that is unrelated to the original designed gene shearing effect). In actual clinical applications, Cas9 can be delivered instantly to the human body in the form of mRNA or protein to achieve the purpose of treatment while greatly reducing off-target effects.

[0003] mRNA delivery is crucial for vaccine development, gene therapy and other fields, and has broad application prospects in the biomedical field. However, it still faces some limitations in practical applications: (1) mRNA stability issues. mRNA is a very unstable molecule that is easily degraded by nucleases in cells. (2) Selection of delivery vectors. Selecting a suitable delivery vector is crucial for mRNA delivery. Currently, commonly used delivery vectors include lipid nanoparticles (LNPs) and polymer nanoparticles. These vectors need to have good biocompatibility, low immunogenicity and high delivery efficiency. However, existing delivery vectors still have shortcomings in these aspects, such as LNPs may cause immune responses and polymer nanoparticles may have difficulty penetrating cell membranes. (3) Targeted delivery. mRNA delivery requires precise targeting, that is, delivering mRNA to specific cells or tissues. However, current delivery systems often find it difficult to achieve this goal, resulting in the possibility that mRNA is taken up by non-target cells during delivery, reducing the therapeutic effect and increasing the risk of side effects. Therefore, in order to work in vivo, mRNA requires a safe, effective and stable delivery system to protect mRNA from degradation and allow it to be taken up by cells and released within cells. At the same time, challenges in terms of safety, effectiveness and delivery efficiency also need to be further studied and addressed.

[0004] PP7 coat protein (PCP) is an important component of phage PP7. It plays a key role in the structure and function of phages, and has multiple functions such as protecting nucleic acids, participating in the infection process, and serving as a display platform. PCP is a small protein that can specifically recognize and bind to certain stem-loop RNA molecules (PP7 RNA).

[0005] The prior art does not disclose a high-efficiency VLP vector based on the PP7 RNA stem-loop structure and research on its use in delivering mRNA. Summary of the invention

[0006] In order to solve the above problems, the present invention combines the phage capsid protein and the stem-loop structure to obtain a PCP-PP7 RNA combination with high specific binding and delivery efficiency, thereby improving the mRNA delivery efficiency of the VLP vector and the CRISPR-Cas9 editing efficiency.

[0007] In one aspect, the present invention provides the use of the PP7 RNA stem-loop structure in the preparation of delivery RNA, the use of which includes but is not limited to:

[0008] (1) Use in achieving gene editing and gene therapy drugs;

[0009] (2) Use of RNA expressing tumor antigens and viral antigens in the preparation of vaccines;

[0010] (3) Use in expressing cell reprogramming factors for producing pluripotent stem cells;

[0011] (4) Use in expressing cell reprogramming factors for modifying cell functions;

[0012] (5) Use in delivering chimeric antigen receptor RNA for the preparation of cellular immunotherapy drugs.

[0013] Specifically, the RNA includes but is not limited to: mRNA, gRNA, siRNA, miRNA, ASO, rRNA or various non-coding RNAs.

[0014] More specifically, the RNA may be mRNA or gRNA.

[0015] Preferably, the RNA may be mRNA.

[0016] Specifically, the number of the PP7 RNA stem-loop structures is 5-8.

[0017] Preferably, the number of the PP7 RNA stem-loop structures is 6-7.

[0018] Further preferably, the number of the PP7 RNA stem-loop structures is 6.

[0019] In yet another aspect, the present invention provides a lentivirus-like particle, wherein the lentivirus-like particle comprises a PP7 RNA stem-loop structure.

[0020] Specifically, the packaging plasmid of the lentivirus-like particles may include pCMV-Cas9-PP7 RNA plasmid, pLV-egfp-U3-sp.gRNA plasmid, PMDlg / pRRE-D64V, PCP-PH-Gag-Pol-D64V, PMD.2G and pRSV-REV;

[0021] The number of PP7 RNA on the pCMV-Cas9-PP7 RNA plasmid can be 5-8;

[0022] The gRNA sequence on the pLV-egfp-U3-sp.gRNA plasmid is: SEQ ID NO.3;

[0023] The amino acid D at position 64 of the Integrase gene in the pol region of the PMDlg / pRRE-D64V plasmid is mutated to V;

[0024] The PCP-Gag-Pol gene sequence on the PCP-PH-Gag-Pol-D64V plasmid is SEQ ID NO.2.

[0025] Preferably, the number of the PP7 RNAs can be 6-7.

[0026] Further preferably, the number of the PP7 RNA is 6.

[0027] Specifically, the Cas9-6×PP7 RNA gene sequence on the pCMV-Cas9-PP7 RNA plasmid is SEQ ID NO.1.

[0028] In another aspect, the present invention provides a method for preparing lentivirus-like particles, the preparation method comprising the following steps:

[0029] S1, plasmid construction;

[0030] S2, transfected and infected cells;

[0031] S3, removal of residual plasmid;

[0032] S4. VLP concentration.

[0033] Specifically, the plasmids include pCMV-Cas9-PP7 RNA plasmid, pLV-egfp-U3-sp.gRNA plasmid, PMDlg / pRRE-D64V, PCP-PH-Gag-Pol-D64V, PMD.2G and pRSV-REV;

[0034] More specifically, the number of PP7 RNA on the pCMV-Cas9-PP7 RNA plasmid can be 5-8;

[0035] Preferably, the number of the PP7 RNAs can be 6-7.

[0036] Further preferably, the number of the PP7 RNA is 6.

[0037] More preferably, the Cas9-6×PP7 RNA gene sequence on the pCMV-Cas9-PP7 RNA plasmid is SEQ ID NO.1.

[0038] More specifically, the gRNA sequence on the pLV-egfp-U3-sp.gRNA plasmid is: SEQ ID NO.3.

[0039] More specifically, the aspartic acid at position 64 of the Integrase gene in the pol region of the PMDlg / pRRE-D64V plasmid is mutated to valine.

[0040] More specifically, the PCP-Gag-Pol gene sequence on the PCP-PH-Gag-Pol-D64V plasmid is SEQID NO.2.

[0041] In another aspect, the present invention provides the use of the aforementioned lentivirus-like particles in preparing RNA for delivery, wherein the use includes but is not limited to:

[0042] (1) Use in achieving gene editing and gene therapy drugs;

[0043] (2) Use of RNA expressing tumor antigens and viral antigens in the preparation of vaccines;

[0044] (3) Use in expressing cell reprogramming factors for producing pluripotent stem cells;

[0045] (4) Use in expressing cell reprogramming factors for modifying cell functions;

[0046] (5) Use in delivering chimeric antigen receptor RNA for the preparation of cellular immunotherapy drugs.

[0047] Specifically, the RNA includes mRNA, gRNA, siRNA, miRNA, ASO, rRNA or multiple non-coding RNAs.

[0048] More specifically, the RNA may be mRNA or gRNA.

[0049] Preferably, the RNA may be mRNA.

[0050] The technical effects achieved by the present invention are:

[0051] (1) Under the same VLP infection dose conditions, the editing efficiency of the PCP and PP7 RNA combination was significantly higher than that of the MS2C and Stem loop combination.

[0052] (2) The technical solution of the present invention greatly reduces the risk of "off-target effect" of traditional lentiviral delivery.

[0053] (3) The technical solution of the present invention improves the disadvantage of low delivery efficiency of existing VLP vectors and develops a relatively more efficient delivery vector for transient expression. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 To detect the effect of removing residual plasmids.

[0055] Figure 2 Fluorescence observation was performed 96 h after infection.

[0056] Figure 3 This is the flow cytometry detection result of VLP-PCP-PP7 RNA group.

[0057] Figure 4 This is the flow cytometry detection result of the VLP-MS2C-Stem loop group.

[0058] Figure 5 This is the flow cytometry test result of the NC group.

[0059] Figure 6 AAVS1 editing efficiency of three groups analyzed for T7E1; *P<0.05.

[0060] Figure 7 AAVS1 gene editing efficiency in the VLP-PCP-PP7 RNA group.

[0061] Figure 8 AAVS1 gene editing efficiency in the VLP-MS2C-Stem loop group.

[0062] Fig. 9This is a significant difference analysis of AAVS1 gene editing efficiency between VLP-PCP-PP7 RNA and VLP-MS2C-Stem loop groups; **P<0.01.

[0063] Fig.10 Detection of Cas9 protein expression in cells infected with VLP-PCP-PP7 RNA and VLP-MS2C-Stem loop groups at different time periods.

[0064] Fig.11 This is the map of the pLV-egfp-U3-sp.gRNA plasmid. DETAILED DESCRIPTION

[0065] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0066] Example 1

[0067] 1.1 Plasmid construction

[0068] (1) pCMV-Cas9-6×PP7 RNA plasmid

[0069] The sequence between GFP and poly(A) in the pCMV-GFP plasmid (manufacturer: Miaoling Plasmid Platform, catalog number: P20780) was replaced with ATG+cas9 sequence+TAA+6×PP7 RNA sequence. This was done in two steps: first inserting the Cas9 sequence, then inserting the 6×PP7 RNA sequence to obtain the pCMV-Cas9-6×PP7 RNA plasmid.

[0070] Cas9-6×PP7 RNA gene sequence on pCMV-Cas9-6×PP7 RNA plasmid (SEQ ID NO.1):

[0071]

[0072] (2) pLV-egfp-U3-sp.gRNA plasmid

[0073] Insert the EGFP sequence into the shuttle plasmid in the third-generation lentiviral packaging system. Insert the U6 promoter sequence into the U3 region of 3'LTR to obtain the pLV-egfp plasmid. Then anneal AAVS1 gRNA-F (SEQ ID NO.4: CACCGGGGCCACTAGGGACAGGAT) and AAVS1 gRNA-R (SEQ ID NO.5: AAACATCCTGTCCCTAGTGGCCCC) to obtain a double-stranded AAVS1 gRNA. Then, the pLV-egfp plasmid was digested with Aar I enzyme (manufacturer: ThermoFisher Scientific, catalog number: ER1581), and the AAVS1 gRNA double-stranded was cloned into the pLV-egfp plasmid to obtain the pLV-egfp-U3-AAVS1-sp.gRNA plasmid. The AAVS1 gRNA sequence is (SEQ ID NO.3): GGGGCCACTAGGGACAGGAT.

[0074] (3) PMDlg / pRRE-D64V plasmid transformation

[0075] The amino acid GAT (D) at position 64 of the Integrase gene in the pol region of the pMDLg-pRRE plasmid (sequence from Addgeen (catalog number: #12251), synthesized by GenScript Biotech Co., Ltd.) in the third-generation lentiviral packaging system was mutated to GTT (V).

[0076] (4) PCP-PH-Gag-Pol-D64V plasmid transformation

[0077] The pMS2M-PH-Gag-Pol-D64V plasmid was purchased from Miaoling Plasmid Platform, catalog number: P37491, and the MS2C gene in the plasmid was replaced with the PCP gene.

[0078] PCP-Gag-Pol gene sequence on PCP-PH-Gag-Pol-D64V plasmid (SEQ ID NO.2):

[0079]

[0080] (5) PMD.2G (sequence from Addgeen (catalog number: #12259), synthesized by GenScript Biotech Co., Ltd.) and pRSV-REV plasmid (sequence from Addgeen (catalog number: #12253), synthesized by GenScript Biotech Co., Ltd.) are from the third-generation lentiviral plasmid.

[0081] 1.2 Transfection and infection

[0082] 1) Plate cells in a 15 cm cell culture dish, adding 1.6E5 cells / cm2 to each well. 2 HEK-293T cells, cultured for 24 h.

[0083] 2) After 24 hours, the cell culture medium in the 15 cm well plate was replaced with 30 mL 2% FBSDMEM and incubated at 37°C.

[0084] 3) Transfection was performed in a 15 cm cell culture medium at a ratio of 1 μg DNA (total) to PEI (polyplus) to 2 μL. The transfection dose was as follows:

[0085] Plasmid name Plasmid transfection amount per well (μg) PMD.2G 7.2 pRSV-REV 5.77 pCMV-Cas9-6×PP7 RNA 25 pLV-egfp-U3-sp.gRNA 25 PCP-PH-Gag-Pol-D64V 12.5 pMDlg / pRRE-D64V 12.5

[0086] 10% FBSDMEM was replaced at 6 h after transfection, and 30 mL of supernatant was collected at 72 h.

[0087] 4) Removal of residual plasmid

[0088] Nuclease was added to the supernatant. After 1 hour of reaction, the nucleic acid was tested for the removal of residual plasmid. The test results were as follows: Figure 1 The indicated residual plasmids were completely removed.

[0089] 5) VLP Concentration

[0090] The supernatant after the removal of nucleic acid was centrifuged at 4°C and 25000rpm for 2h. After the supernatant was discarded, 1 / 50 of the original supernatant volume of PBS was added, and the solution was dissolved and resuspended overnight. The volume after concentration was 600uL.

[0091] 6) Transduction titer detection (flow cytometry):

[0092] Plate the cells 12 hours in advance in a 24-well plate with 1E5 cells per well. In the infection experiment, three groups were set up: NC group: cells were added with DMEM; VLP-MS2C-Stem loop group: cells were added with VLPs based on the reported MS2C-Stem loop structure as a control; VLP-PCP-PP7 RNA group: cells were added with VLPs based on the PCP-PP7 RNA structure. Cells were collected 96 hours after infection, and the proportion of green fluorescence-positive cells was detected by flow cytometry to calculate the transduction titer.

[0093] The transduction titer calculation results are shown in the following table:

[0094] Grouping Transduction titer (green fluorescence positive) VLP-PCP-PP7 RNA group 7.56E7 TU / mL VLP-MS2C-Stem loop group 2.299E8 TU / mL

[0095] The 96h green fluorescence observation results are as follows Figure 2 shown.

[0096] Flow test results:

[0097] The VLP was diluted 1000 times, and 100 μL was taken to infect 1E5 293T cells. Flow cytometry showed that the ratio of green fluorescence positive cells was Figure 3-Figure 5 The transduction titer of the VLP-PCP-PP7 RNA group was calculated to be 7.56E7 TU / mL, and the transduction titer of the VLP-MS2C-Stem loop group was 2.299E8 TU / mL.

[0098] 7) AAVS1 editing efficiency detection

[0099] The transfected and concentrated VLP supernatant was used to infect 293T cells. The cells were collected 5 days after infection. T7E1 was used to detect whether the AAVS1 gene was edited, and the grayscale was scanned to calculate the editing efficiency. The detection primers are as follows:

[0100] Primer name Primer sequences SEQ ID NO. T7E1-AAVS1 F CCAGACAGCCGCGTCAGA SEQ ID NO.6 T7E1-AAVS1 R CCTGCCGCCTCCTTCAGG SEQ ID NO.7

[0101] The results of the T7E1 editing efficiency test are as follows Figure 6 As shown, under the conditions of the same VLP infection dose, the editing efficiency of the PCP and PP7 RNA combination was significantly higher than that of the MS2C and Stem loop combination.

[0102] The transfected and concentrated VLP supernatant was used to infect 293T cells. After 5 days of infection, the cells were collected and the cell DNA was extracted. After amplification with T7E1-AAVS1 F primers, Sanger sequencing was performed, and then the AAVS1 gene editing efficiency was detected by TIDE. The TIDE detection results are shown in Figure 2. Figure 7-Figure 9 As shown, under the conditions of the same VLP infection dose, the editing efficiency of the combination of PCP and PP7 RNA was significantly higher than that of the combination of MS2C and Stem loop.

[0103] 8) Cas9 WB detection

[0104] 12 hours before infection, cells were plated in 6-well cell culture plates with 1E6 cells per well. After cells adhered to the wall, VLP-PCP-PP7 RNA group and VLP-MS2C-Stem loop group VLPs were added to the cells. Cells were collected 24h, 48h and 72h after infection for WB detection of Cas9 expression.

[0105] Test results such as Fig.10 As shown, the expression of Cas9 protein can be detected in both the VLP-PCP-PP7 RNA group and the VLP-MS2C-Stem loop group at 24h and 48h after infection, while the expression of Cas9 protein cannot be detected at 72h after infection, indicating that the Cas9 protein will be degraded at 72h, greatly reducing the risk of "off-target effect" of traditional lentiviral delivery.

Claims

1. Use of the PP7 RNA stem-loop structure in the preparation of delivery RNA, the uses comprising: (1) Use in achieving gene editing and gene therapy drugs; (2) Use of RNA expressing tumor antigens and viral antigens in the preparation of vaccines; (3) Use in expressing cell reprogramming factors for producing pluripotent stem cells; (4) Use in expressing cell reprogramming factors for modifying cell functions; (5) Use of chimeric antigen receptor RNA in the preparation of cellular immunotherapy drugs.

2. The use according to claim 1, characterized in that The RNA includes mRNA, gRNA, siRNA, miRNA, ASO, rRNA or various non-coding RNAs.

3. The use according to claim 1 or 2, characterized in that The number of the PP7 RNA stem-loop structures is 5-8.

4. A lentivirus-like particle, characterized in that The lentivirus-like particle comprises a PP7 RNA stem-loop structure.

5. The lentivirus-like particle according to claim 4, characterized in that The packaging plasmids of the lentivirus-like particles include pCMV-Cas9-PP7 RNA plasmid, pLV-egfp-U3-sp.gRNA plasmid, PMDlg / pRRE-D64V, PCP-PH-Gag-Pol-D64V, PMD.2G and pRSV-REV; The number of PP7 RNA on the pCMV-Cas9-PP7 RNA plasmid is 5-8; The gRNA sequence on the pLV-egfp-U3-sp.gRNA plasmid is: SEQ ID NO.3; The amino acid D at position 64 of the Integrase gene in the pol region of the PMDlg / pRRE-D64V plasmid is mutated to V; The PCP-Gag-Pol gene sequence on the PCP-PH-Gag-Pol-D64V plasmid is SEQ ID NO.

2.

6. The lentivirus-like particle according to claim 5, characterized in that The number of the PP7 RNA is 6-7, preferably 6.

7. The lentivirus-like particle according to claim 5, characterized in that The Cas9-6×PP7 RNA gene sequence on the pCMV-Cas9-PP7 RNA plasmid is SEQ ID NO.

1.

8. A method for preparing lentivirus-like particles, characterized in that: The preparation method comprises the following steps: S1, plasmid construction; S2, transfected and infected cells; S3, removal of residual plasmid; S4, VLP concentration; The plasmids include pCMV-Cas9-PP7 RNA plasmid, pLV-egfp-U3-sp.gRNA plasmid, PMDlg / pRRE-D64V, PCP-PH-Gag-Pol-D64V, PMD.2G and pRSV-REV; The Cas9-6×PP7 RNA gene sequence on the pCMV-Cas9-PP7 RNA plasmid is SEQ ID NO.1; The gRNA sequence on the pLV-egfp-U3-sp.gRNA plasmid is: SEQ ID NO.3; The aspartic acid at position 64 of the Integrase gene in the pol region of the PMDlg / pRRE-D64V plasmid is mutated to valine; The PCP-Gag-Pol gene sequence on the PCP-PH-Gag-Pol-D64V plasmid is SEQ ID NO.

2.

9. Use of the lentivirus-like particle according to any one of claims 4 to 7 in preparing RNA for delivery, the use comprising: (1) Use in achieving gene editing and gene therapy drugs; (2) Use of RNA expressing tumor antigens and viral antigens in the preparation of vaccines; (3) Use in expressing cell reprogramming factors for producing pluripotent stem cells; (4) Use in expressing cell reprogramming factors for modifying cell functions; (5) Use in delivering chimeric antigen receptor RNA for the preparation of cellular immunotherapy drugs.

10. The use according to claim 9, characterized in that The RNA includes mRNA, gRNA, siRNA, miRNA, ASO, rRNA or various non-coding RNAs.

Citation Information

Patent Citations

  • Lentiviral vector and method thereof for delivering external source RNA

    CN108504689A

  • Particle for the encapsidation of a genome engineering system

    CN109415415A

  • Lentiviral vector for delivering exogenous RNP and preparation method of lentiviral vector

    CN110684804A

  • Gene targeting

    CN112585272A

  • SgRNA for targeted degradation of PCSK9 mRNA and gene editing vector and application thereof

    CN114214327A